Amgen Inc (AMGN) 160.85 $AMGN
Midday Glance: Biotechnology companies
AP - Thu Nov 13, 12:28PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), CELG: 107.43 (-0.82)
Early Glance: Biotechnology companies
AP - Thu Nov 13, 11:16AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), CELG: 107.43 (-0.82)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.86 (+0.02), HLF: 37.85 (+0.04), NVO: 44.02 (-0.30), VVUS: 3.26 (-0.08), AMGN: 160.85 (-1.08), GSK: 45.66 (+0.04), ARNA: 4.61 (-0.09)
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CZR, OREX, AMZN, TM and AMGN.
AMZN: 316.48 (+4.97), OREX: 5.86 (+0.02), AMGN: 160.85 (-1.08), TM: 119.82 (+1.03), CZR: 16.51 (+2.84)
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.39 (-0.16), AMGN: 160.85 (-1.08)
The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead
PR Newswire - Thu Nov 13, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dendreon (Nasdaq
NDN-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report), AbbVie (NYSE:ABBV-Free Report) and Gilead (Nasdaq:GILD-Free Report).
AMGN: 160.85 (-1.08)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 109.07 (+0.32), MRK: 59.54 (+0.23), AMGN: 160.85 (-1.08), LLY: 67.68 (+0.28), GSK: 45.66 (+0.04), BMY: 57.80 (-0.81)
Final Glance: Biotechnology companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), CELG: 107.43 (-0.82)
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
PR Newswire - Wed Nov 12, 3:35PM CST
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on Tuesday, Nov. 18, at 6 p.m. CT. Rob Scott, M.D., vice president of Global Development at Amgen, and Scott Wasserman, M.D., executive medical director of Global Development at Amgen, along with clinical investigators, will participate in this call to discuss Amgen's cardiovascular program, including the evolocumab data presented at the congress.
AMGN: 160.85 (-1.08)
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
PR Newswire - Wed Nov 12, 3:01PM CST
Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago, including data from studies evaluating evolocumab, an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 160.85 (-1.08)
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 109.07 (+0.32), PFE: 30.42 (unch), MRK: 59.54 (+0.23), AMGN: 160.85 (-1.08), MO: 49.45 (+0.12), CVX: 116.45 (-1.20)
14.2% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Wed Nov 12, 11:15AM CST
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on October 21st, 2014 at $141.25. In approximately 3 weeks, Amgen has returned 14.22% as of today's recent price of $161.34.
AMGN: 160.85 (-1.08)
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide
PR Newswire - Wed Nov 12, 8:00AM CST
The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and, for the first time, Japan. A signature Foundation initiative, the Amgen Scholars Program aims to inspire the next generation of innovators by providing undergraduates with hands-on summer research opportunities at many of the world's premier educational institutions. In this next phase of the initiative, the National Institutes of Health (NIH), Harvard University, ETH Zurich, Institut Pasteur, Kyoto University, and the University of Tokyo are being added to the already distinguished group of host institutions.
AMGN: 160.85 (-1.08)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.72 (-3.96), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), DNDN: 0.13 (-0.03), AMGN: 160.85 (-1.08), ABBV: 63.63 (-0.13), REGN: 402.63 (+1.52)
Melanoma Therapeutics Market to 2020: Market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020
M2 - Wed Nov 12, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/c5237g/melanoma) has announced the addition of the "Melanoma Therapeutics Market to 2020 " report to their offering. The melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4% This report is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas. Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth. Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Melanoma Pipeline 5 Market Forecast to 2020 6 Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/c5237g/melanoma
AMGN: 160.85 (-1.08)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.71 (+1.41), ACT: 241.63 (+1.01), CBG: 32.69 (-0.02), HCP: 43.92 (+0.62), BCR: 165.59 (+0.38), PCG: 49.77 (-0.37), AMGN: 160.85 (-1.08), CB: 101.47 (-0.05), SRE: 109.51 (-1.14), PLD: 41.10 (+0.10), HSP: 58.09 (unch), TWX: 78.98 (+1.30), KIM: 24.74 (+0.14), CMI: 144.52 (-1.97), ALXN: 193.59 (-0.10), ESS: 200.52 (+0.08), ABBV: 63.63 (-0.13), CAT: 101.11 (-1.88), AAPL: 112.82 (+1.57)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.51 (-0.03), JNJ: 109.07 (+0.32), IDRA: 2.45 (-0.11), DERM: 16.24 (-0.01), MRK: 59.54 (+0.23), PFE: 30.42 (unch), AZN: 74.53 (+0.27), AMGN: 160.85 (-1.08), GSK: 45.66 (+0.04), HSP: 58.09 (unch), NVS: 94.38 (+1.72), CELG: 107.43 (-0.82)
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - Tue Nov 11, 3:01PM CST
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 74.53 (+0.27), AMGN: 160.85 (-1.08)
Midday Glance: Biotechnology companies
AP - Thu Nov 13, 12:28PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), CELG: 107.43 (-0.82)
Early Glance: Biotechnology companies
AP - Thu Nov 13, 11:16AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), CELG: 107.43 (-0.82)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.86 (+0.02), HLF: 37.85 (+0.04), NVO: 44.02 (-0.30), VVUS: 3.26 (-0.08), AMGN: 160.85 (-1.08), GSK: 45.66 (+0.04), ARNA: 4.61 (-0.09)
Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
PR Newswire - Thu Nov 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CZR, OREX, AMZN, TM and AMGN.
AMZN: 316.48 (+4.97), OREX: 5.86 (+0.02), AMGN: 160.85 (-1.08), TM: 119.82 (+1.03), CZR: 16.51 (+2.84)
Biothera Names Carey Anderson VP of Regulatory Affairs
Business Wire - Thu Nov 13, 8:30AM CST
Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business.
MACK: 8.39 (-0.16), AMGN: 160.85 (-1.08)
The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead
PR Newswire - Thu Nov 13, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dendreon (Nasdaq
NDN-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report), AbbVie (NYSE:ABBV-Free Report) and Gilead (Nasdaq:GILD-Free Report). AMGN: 160.85 (-1.08)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 109.07 (+0.32), MRK: 59.54 (+0.23), AMGN: 160.85 (-1.08), LLY: 67.68 (+0.28), GSK: 45.66 (+0.04), BMY: 57.80 (-0.81)
Final Glance: Biotechnology companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), CELG: 107.43 (-0.82)
Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
PR Newswire - Wed Nov 12, 3:35PM CST
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on Tuesday, Nov. 18, at 6 p.m. CT. Rob Scott, M.D., vice president of Global Development at Amgen, and Scott Wasserman, M.D., executive medical director of Global Development at Amgen, along with clinical investigators, will participate in this call to discuss Amgen's cardiovascular program, including the evolocumab data presented at the congress.
AMGN: 160.85 (-1.08)
Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
PR Newswire - Wed Nov 12, 3:01PM CST
Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014 being held Nov. 15-19 in Chicago, including data from studies evaluating evolocumab, an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 160.85 (-1.08)
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 109.07 (+0.32), PFE: 30.42 (unch), MRK: 59.54 (+0.23), AMGN: 160.85 (-1.08), MO: 49.45 (+0.12), CVX: 116.45 (-1.20)
14.2% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Wed Nov 12, 11:15AM CST
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on October 21st, 2014 at $141.25. In approximately 3 weeks, Amgen has returned 14.22% as of today's recent price of $161.34.
AMGN: 160.85 (-1.08)
The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide
PR Newswire - Wed Nov 12, 8:00AM CST
The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe, and, for the first time, Japan. A signature Foundation initiative, the Amgen Scholars Program aims to inspire the next generation of innovators by providing undergraduates with hands-on summer research opportunities at many of the world's premier educational institutions. In this next phase of the initiative, the National Institutes of Health (NIH), Harvard University, ETH Zurich, Institut Pasteur, Kyoto University, and the University of Tokyo are being added to the already distinguished group of host institutions.
AMGN: 160.85 (-1.08)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.72 (-3.96), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), DNDN: 0.13 (-0.03), AMGN: 160.85 (-1.08), ABBV: 63.63 (-0.13), REGN: 402.63 (+1.52)
Melanoma Therapeutics Market to 2020: Market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020
M2 - Wed Nov 12, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/c5237g/melanoma) has announced the addition of the "Melanoma Therapeutics Market to 2020 " report to their offering. The melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4% This report is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas. Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth. Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Melanoma Pipeline 5 Market Forecast to 2020 6 Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/c5237g/melanoma
AMGN: 160.85 (-1.08)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.71 (+1.41), ACT: 241.63 (+1.01), CBG: 32.69 (-0.02), HCP: 43.92 (+0.62), BCR: 165.59 (+0.38), PCG: 49.77 (-0.37), AMGN: 160.85 (-1.08), CB: 101.47 (-0.05), SRE: 109.51 (-1.14), PLD: 41.10 (+0.10), HSP: 58.09 (unch), TWX: 78.98 (+1.30), KIM: 24.74 (+0.14), CMI: 144.52 (-1.97), ALXN: 193.59 (-0.10), ESS: 200.52 (+0.08), ABBV: 63.63 (-0.13), CAT: 101.11 (-1.88), AAPL: 112.82 (+1.57)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.51 (-0.03), JNJ: 109.07 (+0.32), IDRA: 2.45 (-0.11), DERM: 16.24 (-0.01), MRK: 59.54 (+0.23), PFE: 30.42 (unch), AZN: 74.53 (+0.27), AMGN: 160.85 (-1.08), GSK: 45.66 (+0.04), HSP: 58.09 (unch), NVS: 94.38 (+1.72), CELG: 107.43 (-0.82)
Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - Tue Nov 11, 3:01PM CST
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 74.53 (+0.27), AMGN: 160.85 (-1.08)
